| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02210663 | Advanced Solid Tumors | Drug: veliparib (ABT-888) | AbbVie | Phase 1 | 2014-07-01 | 2016-07-19 |
| NCT02158507 | Metastatic Triple Negative Breast Cancer | Drug: Combination of Veliparib + Lapatinib | University of Alabama at Birmingham|Scariot Foundation|GlaxoSmithKline|AbbVie | | 2014-07-01 | 2016-12-28 |
| NCT02289690 | Small Cell Lung Cancer | Drug: Veliparib|Drug: Carboplatin|Drug: Etoposide | AbbVie | Phase 2 | 2014-10-01 | 2017-02-22 |
| NCT01853306 | Oncology|BRCA Mutated|High Grade Serous Ovarian Cancer|BRCA Mutated Breast Cancer | Drug: Veliparib | AbbVie | Phase 1 | 2013-03-01 | 2017-02-06 |
| NCT01123876 | Gastric Cancer | Drug: Veliparib | AbbVie (prior sponsor, Abbott)|AbbVie | Phase 1 | 2010-03-01 | 2015-01-20 |
| NCT01690598 | Ovarian Cancer | Drug: Veliparib|Drug: Topotecan | Vejle Hospital|Abbott | Phase 1|Phase 2 | 2012-11-01 | 2015-06-09 |
| NCT01199224 | Solid Tumors | Drug: veliparib|Drug: veliparib|Drug: veliparib|Drug: veliparib | Abbott | Phase 1 | 2010-06-01 | 2011-02-03 |
| NCT02723864 | Neoplasms | Drug: Veliparib + VX-970 + Cisplatin | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) | Phase 1 | 2016-03-22 | 2017-03-21 |
| NCT00892736 | Basal-Like Breast Carcinoma|BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Breast Carcinoma|Estrogen Receptor Negative|HER2/Neu Negative|Hereditary Breast and Ovarian Cancer Syndrome|Ovarian Carcinoma|Pancreatic Carcinoma|Progesterone Receptor Negative|Prostate Carcinoma|Recurrent Breast Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Solid Neoplasm|Triple-Negative Breast Carcinoma | Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Veliparib | National Cancer Institute (NCI) | Phase 1 | 2009-04-01 | 2016-06-30 |
| NCT01351909 | HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer | Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Drug: Veliparib | National Cancer Institute (NCI) | Phase 1 | 2011-05-01 | 2017-02-16 |
| NCT01540565 | BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ovarian Epithelial Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma | Other: Laboratory Biomarker Analysis|Drug: Veliparib | National Cancer Institute (NCI) | Phase 2 | 2012-04-01 | 2017-02-02 |
| NCT01193140 | Solid Tumor Cancers | Drug: veliparib|Drug: Temozolomide | Abbott | Phase 2 | 2010-07-01 | 2012-11-16 |
| NCT01434316 | BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Solid Neoplasm | Drug: Dinaciclib|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Veliparib | National Cancer Institute (NCI) | Phase 1 | 2011-11-01 | 2017-01-31 |
| NCT01908478 | Pancreatic Cancer | Drug: Veliparib|Drug: Gemcitabine|Radiation: Intensity modulated radiation therapy | Cedars-Sinai Medical Center|AbbVie | Phase 1 | 2013-07-01 | 2017-02-17 |
| NCT01589419 | Locally Advanced Rectal Cancer | Drug: veliparib|Drug: capecitabine|Radiation: radiation | AbbVie (prior sponsor, Abbott)|AbbVie | Phase 1 | 2012-06-01 | 2015-01-20 |
| NCT02860819 | Testicular Cancer | Drug: Veliparib|Drug: Gemcitabine|Drug: Carboplatin | National Cancer Institute, Slovakia | Phase 2 | 2016-07-01 | 2016-08-04 |
| NCT01472783 | Recurrent, Epithelial Ovarian Cancer | Drug: Veliparib | Vejle Hospital|Abbott | Phase 1|Phase 2 | 2011-11-01 | 2016-11-15 |
